Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Thomas Freels

Nurse Practitioner Louisville, KY Nurse Practitioner

NPI 1629524053 CMS profile 11169856

3515 Poplar Level Rd, Louisville, KY 40213

Open in the dashboard

General payments

$19,640

319 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Freels of Louisville, KY is reported in the CMS Open Payments database as having received $19,640 across 319 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,097 53
2024 General $4,019 79
2023 General $5,822 63
2022 General $3,767 65
2021 General $1,936 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Freels
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Thomas Freels were reported at $4,097. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Thomas Freels Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,936 $135 $40–$426 $132
2022 $3,767 $152 $48–$470 $149
2023 $5,822 $166 $54–$529 $160
2024 $4,019 $173 $55–$556 $164
2025 $4,097 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Saluda Medical Americas, Inc. $4,576 54 payments
  2. Abbott Laboratories $4,439 60 payments
  3. Medtronic, Inc. $3,259 52 payments
  4. Boston Scientific Corporation $2,043 30 payments
  5. Spinal Simplicity, LLC $1,173 7 payments
  6. Curonix LLC $1,064 11 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $509 36 payments
  8. Vertos Medical, Inc. $441 4 payments
  9. Stimwave Technologies Incorporated $417 5 payments
  10. Nevro Corp. $313 7 payments
  11. Other $1,406 53 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,208 288 payments
  2. Travel and Lodging $6,433 31 payments
Products named General payments · program years 2021–2025
  1. Evoke $3,933 45 payments
  2. SYNCHROMEDII $2,711 34 payments
  3. PROCLAIM Neuromodulation $2,211 33 payments
  4. HA MINUTEMAN G3-R $1,173 7 payments
  5. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $1,064 11 payments
  6. Proclaim IPG $1,046 17 payments
  7. Spectra WaveWriter $1,004 3 payments
  8. Evoke SCS $644 9 payments
  9. INTELLIS ADAPTIVESTIM $537 17 payments
  10. PROCLAIM Neuromodulation $510 4 payments
  11. Other $5,862 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

1,891

Median for Nurse Practitioner: 389

Drug cost

$33,612

Median for Nurse Practitioner: $21,885

Branded share of claims

50.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 944 $17,736
Pregabalin Generic 94 $5,200
Gabapentin Generic 405 $3,841
Amantadine Amantadine Hcl Brand 13 $1,831
Celecoxib Generic 63 $1,558
Tizanidine Hcl Generic 105 $1,233
Tramadol Hcl Generic 104 $852
Methocarbamol Generic 22 $632
Meloxicam Generic 27 $211
Duloxetine Hcl Generic 26 $179

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $89
$89 — —
Qutenza
  • Averitas Pharma Inc. $46
$46 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $19
$19 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

319 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record